The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Supplemental biologics license application submitted for brexucabtagene autoleucel for use in R/R B-cell ALL
Relapsed or refractory (R/R) acute lymphoblastic lymphoma (ALL) is associated with poor prognosis and short overall survival. B-cell ALL is the most common type, accounting for approximately 75% of cases in adults with ALL. Brexucabtagene autoleucel is a CD19-directed, genetically modified, autologous chimeric antigen receptor (CAR) therapy that was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with B-cell ALL in 2017, and now a supplemental biologics license application has been submitted to the FDA.1
The submission is based on the ongoing phase I/II ZUMA-3 trial (NCT02614066) investigating the safety and efficacy of brexucabtagene autoleucel in adult patients with ALL who are refractory to or relapse after standard systemic therapy or hematopoietic stem cell transplantation. If approved, this would be the first licensed CAR T-cell therapy in this patient population.
Brexucabtagene autoleucel has been approved by the FDA in 2020 for R/R mantle cell lymphoma, and it is currently being investigated for the treatment of patients with chronic lymphoblastic lymphoma (CLL) and pediatric ALL.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content